To be eligible to enter this study, the subject will have to meet the following inclusion
1. Korean patients who have been administered Lyrica CR for the first time according to
the current local labeling (indication, dosage and administration).
2. Subjects who have consented to participate in this study by signing the data privacy
Patients meeting any of the following criteria will not be included in the study:
1. Patients who have deviated from local labeling (indication, dosage and administration)
in taking this drug
2. Renal impairment patients with CLCr less than 30 mL/min or who are undergoing
3. Patients who have hypersensitivity to the active substance (pregabalin) or to any of
4. Other patients who are decided to be not prescribed by the investigator under the
routine medical practice, considering the balance the overall risk and benefit, for
example, patients have suicidal behavior and ideation, or have any risk of these,
and/or patients who are in pregnancy or lactation, etc.